Payment overview · 2025
General Payments
$620.65
29 reported records · 15 companies
Healthcare provider profile · identity verified
Tess Barnes, N.P.
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · PRESCOTT, AZ · NPI 1457705154
Verified facts
What the public records show
CMS Open Payments records show Tess Barnes, N.P. received $620.65 in general payments during 2025 across 29 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $173.97 | 28.0% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $89.91 | 14.5% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $55.19 | 8.9% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $48.51 | 7.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.32 | 7.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.42 | 6.7% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.28 | 3.6% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $20.86 | 3.4% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $19.96 | 3.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.83 | 3.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.30 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.04 | 2.9% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $17.91 | 2.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.19 | 2.5% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $13.96 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $620.65 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $139.73 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $105.79 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $89.69 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $75.97 | 4 | 2025 |
Source payment records
|
|||||
| OCTRODE Normalized: octrode |
Device | Abbott Laboratories | $48.51 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $29.49 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.75 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| ORSIRO MISSION Normalized: orsiro mission |
Device | Teleflex LLC | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.83 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.83 | 1 | 2025 |
Source payment records
|
|||||
| KYPHON EXPRESS II KYPHOPAK TRAY Normalized: kyphon express ii kyphopak tray |
Device | Medtronic, Inc. | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| BEVESPI AEROSPHERE Normalized: bevespi aerosphere |
Drug | AstraZeneca Pharmaceuticals LP | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 421 | 117 |
| Atorvastatin Calcium | Atorvastatin Calcium | 287 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 269 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 259 | 79 |
| Lisinopril | Lisinopril | 229 | 71 |
| Losartan Potassium | Losartan Potassium | 228 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 50 |
| Gabapentin | Gabapentin | 149 | 40 |
| Trazodone Hcl | Trazodone Hcl | 117 | 37 |
| Simvastatin | Simvastatin | 106 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 40 |
| Omeprazole | Omeprazole | 92 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 91 | 28 |
| Alprazolam | Alprazolam | 89 | 20 |
| Sertraline Hcl | Sertraline Hcl | 85 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 26 |
| Metformin Hcl Er | Metformin Hcl | 80 | 25 |
| Metformin Hcl | Metformin Hcl | 77 | 24 |
| Tramadol Hcl | Tramadol Hcl | 67 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 28 |
| Meloxicam | Meloxicam | 60 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 20 |
| Potassium Chloride | Potassium Chloride | 57 | 20 |
| Ipratropium Bromide | Ipratropium Bromide | 53 | 19 |
| Lorazepam | Lorazepam | 52 | suppressed |
| Furosemide | Furosemide | 50 | 17 |
| Acyclovir | Acyclovir | 48 | 14 |
| Jardiance | Empagliflozin | 48 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 11 |
| Chlorthalidone | Chlorthalidone | 46 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 12 |
| Glipizide | Glipizide | 43 | 12 |
| Ozempic | Semaglutide | 43 | suppressed |
| Allopurinol | Allopurinol | 42 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 42 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 11 |
| Bupropion Xl | Bupropion Hcl | 41 | 13 |
| Carvedilol | Carvedilol | 41 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 14 |
| Eliquis | Apixaban | 40 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 38 | 16 |
| Ezetimibe | Ezetimibe | 37 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | 12 |
| Spironolactone | Spironolactone | 34 | 12 |
| Glipizide Er | Glipizide | 33 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | 11 |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 16 |
| Celecoxib | Celecoxib | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Estradiol | Estradiol | 29 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 23 |
| Cephalexin | Cephalexin | 27 | 21 |
| Clonidine Hcl | Clonidine Hcl | 26 | 14 |
| Methylprednisolone | Methylprednisolone | 26 | 25 |
| Prednisone | Prednisone | 26 | 14 |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 21 |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | 11 |
| Pregabalin | Pregabalin | 21 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 20 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | 14 |
| Lovastatin | Lovastatin | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Progesterone | Progesterone, Micronized | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 12 |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 13 |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $620.65 · 29 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BEVESPI AEROSPHERE, BREZTRI, CREON, ELIQUIS, FARXIGA, ISTURISA, JARDIANCE, KYPHON EXPRESS II KYPHOPAK TRAY, Kerendia, Leqembi, MOUNJARO, NURTEC ODT, OCTRODE, ORSIRO MISSION, OTEZLA, Ozempic, QULIPTA, RECORLEV, REPATHA, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VUMERITY, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error